Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Antiretroviral drug
Foscarnet
Другие языки:

Foscarnet

Подписчиков: 0, рейтинг: 0
Foscarnet
Foscarnet.svg
Foscarnet ball-and-stick model.png
Clinical data
Trade names Foscavir, Vocarvi, others
Other names phosphonomethanoic acid, dihydroxyphosphinecarboxylic acid oxide
AHFS/Drugs.com Monograph
MedlinePlus a601144
License data
Pregnancy
category
  • AU: B3
Routes of
administration		 Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability NA
Protein binding 14–17%
Elimination half-life 3.3–6.8 hours
Identifiers
  • phosphonoformic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula CH3O5P
Molar mass 126.004 g·mol−1
3D model (JSmol)
  • O=C(O)P(=O)(O)O
  • InChI=1S/CH3O5P/c2-1(3)7(4,5)6/h(H,2,3)(H2,4,5,6) checkY
  • Key:ZJAOAACCNHFJAH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Foscarnet (phosphonomethanoic acid), known by its brand name Foscavir, is an antiviral medication which is primarily used to treat viral infections involving the Herpesviridae family. It is classified as a pyrophosphate analog DNA polymerase inhibitor. Foscarnet is the conjugate base of a chemical compound with the formula HO2CPO3H2 (Trisodium phosphonoformate).

Foscarnet was approved for medical use in 1991.

Medical use

This phosphonic acid derivative (marketed by Clinigen as foscarnet sodium under the trade name Foscavir) is an antiviral medication used to treat herpes viruses, including drug-resistant cytomegalovirus (CMV) and herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2). It is particularly used to treat CMV retinitis. Foscarnet can be used to treat highly treatment-experienced patients with HIV as part of salvage therapy.

Mechanism of action

Foscarnet is a structural mimic of the anion pyrophosphate that selectively inhibits the pyrophosphate binding site on viral DNA polymerases at concentrations that do not affect human DNA polymerases.

In individuals treated with the DNA polymerase inhibitors acyclovir or ganciclovir, HSV or CMV particles can develop mutant protein kinases (thymidine kinase or UL97 protein kinase, respectively) that make them resistant to these antiviral drugs. However, unlike acyclovir and ganciclovir, foscarnet is not activated by viral protein kinases, making it useful in acyclovir- or ganciclovir-resistant HSV and CMV infections.

However, acyclovir- or ganciclovir-resistant mutants with alterations in viral DNA polymerase may also be resistant to foscarnet.

Administration

Foscarnet is administered by intravenous infusion or intravitreous injection.

Side effects

  • Nephrotoxicity — increase in serum creatinine levels and renal injury can occur in patients receiving foscarnet. Other nephrotoxic drugs should be avoided. Nephrotoxicity is usually reversible and can be reduced by dosage adjustment and adequate hydration.
  • Electrolyte disturbances — hypocalcemia and hypomagnesemia can occur and regular monitoring of electrolytes is necessary to avoid clinical toxicity.
  • Genital ulceration — a less common reported side effect which occurs more in men and usually during induction use of foscarnet. It is most likely a contact dermatitis due to high concentrations of foscarnet in urine. It usually resolves rapidly following discontinuation of the drug.
  • CNS — less common side effects of perioral paresthesia, irritability and altered mental states.

Sources

External links

  • "Foscarnet". Drug Information Portal. U.S. National Library of Medicine.
  • "Foscarnet sodium". Drug Information Portal. U.S. National Library of Medicine.

Новое сообщение